These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 25596702)
1. Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer. Geredeli C; Artac M; Yildirim S; Inal A; Dede I; Guler T; Boruban MC; Koral L; Karaagac M; Zamani AG; Altinok T; Aribas O; Bozcuk H; Demirkazik A Tumour Biol; 2015 Jun; 36(6):4279-85. PubMed ID: 25596702 [TBL] [Abstract][Full Text] [Related]
2. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum. Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009 [TBL] [Abstract][Full Text] [Related]
3. Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival. Salimzadeh H; Lindskog EB; Gustavsson B; Wettergren Y; Ljungman D BMC Cancer; 2020 May; 20(1):409. PubMed ID: 32397974 [TBL] [Abstract][Full Text] [Related]
4. The XRCC1 and TP53 gene polymorphisms are associated with advanced-stage disease and early distant metastasis at diagnosis in non-small cell lung cancer. Karaağaç M; Geredeli Ç; Yıldırım MS; Altınok T; Dede İ; İnal A; Zamani AG; Kaya B; Demirkazık A; Artaç M J Cancer Res Ther; 2023; 19(5):1248-1254. PubMed ID: 37787291 [TBL] [Abstract][Full Text] [Related]
5. Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. Liu L; Yuan P; Wu C; Zhang X; Wang F; Guo H; Zhong R; Xu Y; Wu J; Yu D; Wu T; Zhang X; Nie S; Miao X; Lin D Lung Cancer; 2011 Jul; 73(1):110-5. PubMed ID: 21129812 [TBL] [Abstract][Full Text] [Related]
6. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. Yang Y; Xian L Tumour Biol; 2014 Apr; 35(4):2905-21. PubMed ID: 24338713 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy. Mo J; Luo M; Cui J; Zhou S Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845 [TBL] [Abstract][Full Text] [Related]
8. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547 [TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in ERCC1 and ERCC2/XPD genes and carcinogen DNA adducts in human lung. Lee MS; Liu CY; Su L; Christiani DC Lung Cancer; 2015 Jul; 89(1):8-12. PubMed ID: 26001533 [TBL] [Abstract][Full Text] [Related]
11. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy. Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006 [TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Sullivan I; Salazar J; Majem M; Pallarés C; Del Río E; Páez D; Baiget M; Barnadas A Cancer Lett; 2014 Oct; 353(2):160-6. PubMed ID: 25069034 [TBL] [Abstract][Full Text] [Related]
13. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports. Xu TP; Shen H; Liu LX; Shu YQ Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606 [TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients. Pérez-Ramírez C; Cañadas-Garre M; Alnatsha A; Villar E; Valdivia-Bautista J; Faus-Dáder MJ; Calleja-Hernández MÁ Pharmacogenomics J; 2019 Apr; 19(2):164-177. PubMed ID: 29662106 [TBL] [Abstract][Full Text] [Related]
15. No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Yin M; Yan J; Voutsina A; Tibaldi C; Christiani DC; Heist RS; Rosell R; Booton R; Wei Q Lung Cancer; 2011 Jun; 72(3):370-7. PubMed ID: 21075476 [TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. Liao WY; Shih JY; Chang GC; Cheng YK; Yang JC; Chen YM; Yu CJ J Thorac Oncol; 2012 Jun; 7(6):973-81. PubMed ID: 22551904 [TBL] [Abstract][Full Text] [Related]
17. The genetic variations in DNA repair genes ERCC2 and XRCC1 were associated with the overall survival of advanced non-small-cell lung cancer patients. Wang S; Wang J; Bai Y; Wang Q; Liu L; Zhang K; Hong X; Deng Q; Zhang X; He M; Wu T; Xu P; Guo H Cancer Med; 2016 Sep; 5(9):2332-42. PubMed ID: 27465648 [TBL] [Abstract][Full Text] [Related]
18. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Takenaka T; Yano T; Kiyohara C; Miura N; Kouso H; Ohba T; Kometani T; Shoji F; Yoshino I; Maehara Y Lung Cancer; 2010 Jan; 67(1):101-7. PubMed ID: 19361884 [TBL] [Abstract][Full Text] [Related]
19. Associations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancer. Du Y; Su T; Zhao L; Tan X; Chang W; Zhang H; Cao G PLoS One; 2014; 9(6):e99843. PubMed ID: 24933103 [TBL] [Abstract][Full Text] [Related]
20. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]